Prostaglandin E2 inhibits advanced glycation end product-induced adhesion molecule expression on monocytes, cytokine production, and lymphocyte proliferation during human mixed lymphocyte reaction

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 3, 2010, Pages 964-972

  Takahashi, Hideo Kohka ^a   Zhang, Jiyong ^a   Mori, Shuji ^b   Liu, Keyue ^a   Wake, Hidenori ^a   Liu, Rui ^a   Sadamori, Hiroshi ^a   Matsuda, Hiroaki ^a   Yagi, Takahito ^a   Yoshino, Tadashi ^a   Nishibori, Masahiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b SHUJITSU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

11,15 O DIMETHYL PROSTAGLANDIN E2; 16 (3 METHOXYMETHYL)PHENYL OMEGA TETRANOR 3,7 DITHIA PROSTAGLANDIN E1; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ADENYLATE CYCLASE ACTIVATOR; ADVANCED GLYCATION END PRODUCT; B7 ANTIGEN; CD40 ANTIGEN; CYCLIC AMP; CYCLOSPORIN A; FORSKOLIN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; PROSTAGLANDIN E1; PROSTAGLANDIN E2; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; CYTOKINE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROTEIN KINASE INHIBITOR; PTGER2 PROTEIN, HUMAN; PTGER4 PROTEIN, HUMAN;

ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGONISTS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; LYMPHOCYTE; METABOLISM; MIXED LYMPHOCYTE CULTURE;

CELL ADHESION MOLECULES; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTES; MONOCYTES; PROTEIN KINASE INHIBITORS; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956260003     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.169102     Document Type: Article

References (41)

1. Blaheta RA, Hailer NP, Brude N, Wittig B, Leckel K, Oppermann E, Bachmann M, Harder S, Cinatl J, Scholz M, et al. (2000) In vitro analysis of verapamil-induced immunosuppression: potent inhibition of T cell motility and lymphocytic transmigration through allogeneic endothelial cells. Transplantation 69:588-597.
2. Brownlee M, Cerami A, and Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321.
3. Carvalho MF and Soares V (2001) Hyperlipidemia as a risk factor of renal allograft function impairment. Clin Transplant 15:48-52.
4. Coleman RA, Smith WL, and Narumiya S (1994) VIII. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptor and their subtypes. Pharmacol Rev 46:205-229.
5. Cooper ME (2004) Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 17:31S-38S.
6. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, and Ferguson RM (2002) Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 62:1440-1446.
7. Dustin ML and Springer TA (1989) T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 341:619-624.
8. Enomoto M, Adachi H, Yamagishi S, Takeuchi M, Furuki K, Hino A, Hiratsuka A, Takajo Y, and Imaizumi T (2006) Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans. Metabolism 55: 912-917. (Pubitemid 43902894)
9. Filler G, Neuschulz I, Vollmer I, Amendt P, and Hocher B (2000) Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 15:867-871.
10. Fitzsimmons C, Proudfoot D, and Bowyer DE (1999) Monocyte prostaglandins inhibit procollagen secretion by human vascular smooth muscle cells: implications for plaque stability. Atherosclerosis 142:287-293.
11. Ge J, Jia Q, Liang C, Luo Y, Huang D, Sun A, Wang K, Zou Y, and Chen H (2005) Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol 25:2157-2163.
12. Greenfield EA, Nguyen KA, and Kuchroo VK (1998) CD28/B7 costimulation: a review. Crit Rev Immunol 18:389-418.
13. Hartog JW, de Vries AP, Bakker SJ, Graaff R, van Son WJ, van der Heide JJ, Gans RO, Wolffenbuttel BH, de Jong PE, and Smit AJ (2006) Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Nephrol Dial Transplant 21:2263-2269.
14. Hempel SL, Monick MM, and Hunninghake GW (1994) Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 93:391-396.
15. Jespersen B, Thiesson HC, Henriksen C, Therland K, Falk C, Poulsen T, Fogh B, Madsen K, Walther S, and Jensen BL (2009) Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo. Nephrol Dial Transplant 24:1644-1655.
16. Kamei T, Callery MP, and Flye MW (1991) Intragraft delivery of 16,16-dimethyl PGE2 induces donor-specific tolerance in rat cardiac allograft recipients. Transplantation 51:242-546.
17. Kay LJ, Yeo WW, and Peachell PT (2006) Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol 147:707-713.
18. Koh IH, Kim PC, Chung SW, Waddell T, Wong PY, Gorczynski R, Levy GA, and Cohen Z (1992) The effects of 16,16-dimethyl prostaglandin E2 therapy alone and in combination with low-dose cyclosporine on rat small intestinal transplantation. Transplantation 54:592-598.
19. Lorenowicz MJ, Fernandez-Borja M, and Hordijk PL (2007) cAMP signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol 27:1014-1022.
20. Mamputu JC and Renier G (2004) Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. J Leukoc Biol 75:1062-1069.
21. Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, Distant DA, Hong JH, Sommer BG, and Friedman EA (1998) Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 65:380-384.
22. Morichika T, Takahashi HK, Iwagaki H, Yagi T, Saito S, Kubo S, Yoshino T, Akagi T, Mori S, Nishibori M, et al. (2003) Effect of prostaglandin E2 on intercellular adhesion molecule-1 and B7 expression in mixed lymphocyte reaction. Transplantation 75:2100-2105.
23. Nakamura K, Yamagishi SI, Matsui T, Adachi H, Takeuchi M, and Imaizumi T (2007) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med 7:188-190.
24. Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH, and Coffman TM (2001) Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest 108:1229-1235.
25. Noguchi K, Iwasaki K, Shitashige M, Umeda M, Izumi Y, Murota S, and Ishikawa I (2001) Down-regulation of lipopolysaccharide-induced intercellular adhesion molecule-1 expression via EP2/EP4 receptors by prostaglandin E2 in human fibroblasts. Inflammation 25:75-81.
26. Ohashi K, Takahashi HK, Mori S, Liu K, Wake H, Sadamori H, Matsuda H, Yagi T, Yoshino T, Nishibori M, et al. (2010) Advanced glycation end products enhance monocyte activation during human mixed lymphocyte reaction. Clin Immunol 134:345-353.
27. Rizzo M, SivaSai KS, Smith MA, Trulock EP, Lynch JP, Patterson GA, and Mohanakumar T (2000) Increased expression of inflammatory cytokines and adhesion molecules by alveolar macrophages of human lung allograft recipients with acute rejection: decline with resolution of rejection. J Heart Lung Transplant 19:858-865.
28. Schiekofer S, Andrassy M, Chen J, Rudofsky G, Schneider J, Wendt T, Stefan N, Humpert P, Fritsche A, Stumvoll M, et al. (2003) Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 52:621-633.
29. Sezer S, Akgul A, Altinoglu A, Arat Z, Ozdemir FN, and Haberal M (2006) Posttransplant diabetes mellitus: Impact of good blood glucose regulation on renal transplant recipient outcome. Transplant Proc 38:533-536.
30. Shimizu K, Schönbeck U, Mach F, Libby P, and Mitchell RN (2000) Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol 165:3506-3518.
31. Siemann G, Blume R, Grapentin D, Oetjen E, Schwaninger M, and Knepel W (1999) Inhibition of cyclic AMP response element-binding protein/cyclic AMP response element-mediated transcription by the immunosuppressive drugs cyclosporin A and FK506 depends on the promoter context. Mol Pharmacol 55:1094-1100.
32. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, and Suda T (2000) The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141:1554-1559.
33. Swamy-Mruthinti S, Miriam KC, Kumar SK, Biswas J, Ramakrishnan S, Nagaraj RH, and Sulochana KN (2002) Immunolocalization and quantification of advanced glycation end products in retinal neovascular membranes and serum: a possible role in ocular neovascularization. Curr Eye Res 25:139-145.
34. Takahashi HK, Iwagaki H, Tamura R, Yagi T, Yoshino T, Mori S, Tanaka N, and Nishibori M (2005) Effect of antibodies against intercellular adhesion molecule-1, B7, and CD40 on interleukin-18-treated human mixed lymphocyte reaction. J Pharmacol Sci 97:447-450.
35. Takahashi HK, Liu K, Wake H, Mori S, Zhang J, Liu R, Yoshino T, and Nishibori M (2009a) Prostaglandin E2 inhibits advanced glycation end product-induced adhesion molecule expression, cytokine production, and lymphocyte proliferation in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 331:656-670.
36. Takahashi HK, Mori S, Wake H, Liu K, Yoshino T, Ohashi K, Tanaka N, Shikata K, Makino H, and Nishibori M (2009b) Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 330:89-98.
37. Takeuchi M and Yamagishi S (2004) TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses 63:449-452.
38. Tamura R, Takahashi HK, Iwagaki H, Yagi T, Mori S, Yoshino T, Nishibori M, and Tanaka N (2004) Effect of β2-adrenergic receptor agonists on intercellular adhesion molecule (ICAM)-1, B7, and CD40 expression in mixed lymphocyte reaction. Transplantation 77:293-301.
39. van Hooff JP, Christiaans MH, and van Duijnhoven EM (2004) Evaluating mechanisms of post-transplant diabetes mellitus. Nephrol Dial Transplant 19:vi8-vi12.
40. Vlassara H and Palace MR (2002) Diabetes and advanced glycation endproducts. J Intern Med 251:87-101.
41. Zhu SN, Yamada J, Streilein JW, and Dana MR (2000) ICAM-1 deficiency suppresses host allosensitization and rejection of MHC-disparate corneal transplants. Transplantation 69:1008-1013.